Author

J. VanCampen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

B. J. Druker· 2 shared B. M. Smith· 2 shared D. J. Coleman· 2 shared J. E. Maxson· 2 shared J. Estabrook· 2 shared T. P. Braun· 2 shared A. C. Lima· 1 shared A. M. Stendahl· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. J. Druker

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

TAD Evolutionary and functional characterization reveals diversity in mammalian TAD boundary properties and function

M. Okhovat, J. VanCampen, A. C. Lima, K. Nevonen, C. E. Layman, S. Ward, J. Herrera, A. M. Stendahl, R. Yang, L. Harshman, W. Li, R. R. Sheng, Y. Mao, L. Fedorov, B. Ndjamen, , L. Carbone

The paper analyzes TAD boundaries across species to show evolutionary conservation and functional significance, finding ultraconserved boundaries have stronger insulation and CTCF binding.

bioRxiv · Mar 7, 2023Evolutionary Biology

Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

W. M. Yashar, B. M. Smith, D. J. Coleman, J. VanCampen, G. Kong, J. Macaraeg, J. Estabrook, E. Demir, N. Long, D. Bottomly, S. K. McWeeney, J. W. Tyner, B. J. Druker, J. E. Maxson, T. P. Braun

This study shows that combining FLT3 and LSD1 inhibitors synergistically kills FLT3-mutant AML cells by disrupting the MYC super-enhancer complex.

bioRxiv · Jan 17, 2022 · PreprintCancer Biology

PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia

B. M. Smith, J. VanCampen, G. L. Kong, W. Yashar, Y. H. Tsang, W. Horton, D. J. Coleman, J. Estabrook, T. A. Lusardi, G. B. Mills, B. J. Druker, J. E. Maxson, T. P. Braun

This paper shows that combining KIT and LSD1 inhibitors synergistically kills KIT-mutant AML cells by reducing MYC expression and inactivating PI3K/AKT signaling, supporting a clinical trial.

bioRxiv · Aug 24, 2021 · PreprintCancer Biology